Amarin Cuts Costs, Narrows Losses as European Expansion Continues — Amarin Corporation plc

Event summary

Amarin reported a 21% decline in Q4 2025 revenue to $49.2M, driven by a 74% drop in Rest-of-World sales and a 7% decline in U.S. product revenue.
Operating expenses fell 31% to $29.5M, with restructuring costs totaling $4.1M in Q4 2025.
Net loss improved to $(1.2)M from $(48.6)M in Q4 2024, with cash position increasing to $302.6M.
Amarin completed its transition of European sales to Recordati, shifting to a supply-shipment model.
The company published 45 scientific works in 2025 to support its VASCEPA/VAZKEPA franchise.

The big picture

Amarin's strategic shift towards a leaner operating model and its partnership with Recordati reflect broader trends in the pharmaceutical industry towards cost optimization and international expansion. The company's focus on scientific research to support its cardiovascular franchise aligns with the growing emphasis on evidence-based treatments in the healthcare sector. With a strong cash position and reduced losses, Amarin is positioning itself for long-term growth, but must navigate execution risks in its key markets.

What we're watching

Execution Risk: Whether Amarin can sustain its cost-cutting efforts while maintaining market leadership for VASCEPA in the U.S. and expanding VAZKEPA in Europe.
Market Dynamics: The pace at which Amarin can recover from the 21% revenue decline, particularly in the Rest-of-World segment.
Strategic Partnerships: How the long-term partnership with Recordati will impact Amarin's European market penetration and overall financial performance.